Piramal Pharma has launched a high-throughput screening facility
It will add to the existing in-vitro biology capabilities with the addition of primary and secondary screening capabilities of compounds prepared at the Indian site.
Piramal Pharma Limited’s Pharma Solutions (PPS) business is a leading Contract Development and Manufacturing Organization (CDMO) and with this expansion it is well positioned to provide clients with an integrated set of discovery capabilities and the use of a wide range of in vitro screening technology tools to support a broad portfolio of research services.
PPS says the goal is to generate data that provides a superior data package for clients and enhance the company’s value as an outsourcing partner. The benefits of this new investment, it says, will be seen in an improved experience for PPS discovery services customers.
Peter DeYoung, chief executive officer, at Piramal Pharma Solutions said, “Through these enhanced in-vitro biology services, our drug discovery team will be able to provide clients with decision-driving information earlier and will be an even more effective partner in the drug discovery process.”
The integration of chemistry and biology services under one roof, PPS says, promises to add high efficiency to the discovery process. To enable this expansion, the company is committed to bringing in experienced personnel with a demonstrated track record in biology services, complementing the existing technical and operational expertise.
The new high-throughput screening format enables PPS to evaluate and screen large collections using various assay platform technologies including, but not limited to, Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET), Homogeneous Time-Resolved Fluorescence (HTRF), Fluorescence Polarization (FP), absorbance, Luminescence/Electrochemiluminescence (ECL), AlphaScreen, LanthaScreen, flow cytometry and high-content imaging. These platforms will be applicable to a variety of targets including but not limited to G-Protein-Coupled Receptors (GPCRs) and kinases.
PPS offers end-to-end development and manufacturing solutions across the drug life cycle. It has a globally integrated network of facilities in North America, Europe, and Asia. Services including drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial supply of APIs, and finished dosage forms.
The company also offers specialized services such as the development and manufacture of highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptide products and services, and potent solid oral drug products. PPS also offers development and manufacturing services for biologics including vaccines and gene therapies, all made possible through Piramal Pharma Limited’s associate company, Yapan Bio Private Limited.
Overseeing the company, Piramal Pharma Limited (PPL) offers a portfolio of differentiated products and services through 17 global development and manufacturing facilities and a global distribution network in over 100 countries. As well as Piramal Pharma Solutions (PPS), PPL includes an integrated Contract Development and Manufacturing Organization - Piramal Critical Care (PCC), a Complex Hospital Generics business - and the India Consumer Healthcare business, selling over-the-counter products.
